Three years after discussing how to reuse an old scientific measuring device, Novartis scientists are now testing this idea as part of an innovative research project.

Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.

The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.

Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.

Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.

Jean Silveri shares key insights from her legal career.

Over the next 15 years chronic disease like cancer and heart disease will become major killers in Sub-Saharan Africa. A new report from the Economist Intelligence Unit explains why.

Chronic diseases kill 38 million people per year worldwide; almost three-quarters of those deaths occur in low- and middle-income countries. It’s time to act.

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.